Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

Summary

This is a two-part Phase 1b, open-label study of ONT 10 administered in combination with varlilumab. Two different doses of varlilumab will be studied in combination with the single agent recommended dose of ONT 10. Intermediate and/or lower doses of varlilumab or ONT-10 may also be studied at the recommendation of the safety monitoring committee (SMC).

Timeline

Start

2014-11

Primary completion

2016-06

Completion

2016-06

Drugs

Indications